Constarium
← Search

Excel · study · 2026

First-line Sintilimab with P-GEMOX chemotherapy in advanced Extranodal Natural Killer/T cell lymphoma (SPIRIT): a single-arm, multicenter, phase 2 trial

Listed in NCBI GEO

The addition of anti-PD-1 antibody to pegaspargase, gemcitabine and oxaliplatin (P-GEMOX) showed promising activity as first-line therapy in patients with advanced extranodal natural killer/T cell lymphoma, nasal type (ENKTL) in our previous retrospective study.

Description

Here, we assessed the clinical outcomes and multi-omics tumor profiling of sintilimab plus P-GEMOX for patients with previously untreated advanced ENKTL in this phase 2 trial.

Links

Where it is published

Documentation and papers

Topics

From keywords
Life Sciences
Inferred from text
Cancer 65%
Provenance · 1 source records, 8 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE24076313 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[disease].local:disease:cancerenrichment · NCBI GEOkeyword-concept-rules@1.0.0title+description (65%)
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[organism].NCBITaxon:9606source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title